Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of the company’s checkpoint inhibitor Opdivo (nivolumab).
Deciphera Pharmaceuticals Inc.’s shares more than doubled after the drugmaker said a late-stage study met the main goal of helping stomach cancer patients live longer without their disease worsening.
Eli Lilly and Co.’s combination cancer treatment met the main goal of a late-stage clinical trial in testing on patients with a form of lung cancer, the drugmaker announced.
